公开(公告)号：US20250076302A1

公开(公告)日：2025-03-06

申请号：US18740776

申请日：2024-06-12

Applicant: The Cleveland Clinic Foundation

Inventor： Aaron W. Miller ,  Jose Agudelo

IPC: G01N33/68 ,  G01N33/70 ,  G01N33/94

Abstract: The present invention relates to systems, kits, and methods for identifying subjects with increased levels (e.g., in a urine sample) of at least two urine metabolites selected from: butanal; 2-Hydroxy-1,3-dimethoxy-8,9-methylenedioxycoumestan; 6-Methylmercaptopurine; Dimethyl-L-arginine; N-butanoyl-lhomoserine lactone; Hexanoylglycine; Methyl propenyl ketone; Ferulate; 2-Oxoarginine; and 2-Hydroxyestradiol-3-methyl ether, as well as methods of determining if a subject has or is at risk of urinary stone disease based on such urine metabolites. In certain embodiments, the urinary tract of a subject with elevated levels of at least two of the urine metabolites is imaged (e.g., to generate an image showing the size, location, or number of urinary stones present).